Zobrazeno 1 - 10
of 453
pro vyhledávání: '"C. Ronald Scott"'
Autor:
Susan Elliott, Norman Buroker, Jason J. Cournoyer, Anna M. Potier, Joseph D. Trometer, Carole Elbin, Mack J. Schermer, Jaana Kantola, Aaron Boyce, Frantisek Turecek, Michael H. Gelb, C. Ronald Scott
Publikováno v:
Data in Brief, Vol 8, Iss , Pp 915-924 (2016)
In this data article we provide a detailed standard operating procedure for performing a tandem mass spectrometry, multiplex assay of 6 lysosomal enzymes for newborn screening of the lysosomal storage diseases Mucopolysaccharidosis-I, Pompe, Fabry, N
Externí odkaz:
https://doaj.org/article/c73301248a7d40c9a109b27c9bec71a8
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 12, Iss C, Pp 80-81 (2017)
Externí odkaz:
https://doaj.org/article/29d746cbc42741ea92fb41dd77662bf3
Autor:
Martin Sadilek, Warunee Dansithong, C. Ronald Scott, Nicole Ruiz-Schultz, Xinying Hong, Stevie Norcross, Michael H. Gelb, Arun Kumar, Teryn R. Suhr, Maria L. Escolar, Jessica Daiker, Andreas Rohrwasser
Publikováno v:
Genetics in Medicine. 23:555-561
Purpose Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder caused by the deficiency of arylsulfatase A (ARSA), which results in the accumulation of sulfatides. Newborn screening for MLD may be considered in the future as innovative tr
Autor:
Frits A Wijburg, Bernard Bénichou, Daniel G Bichet, Lorne A Clarke, Gabriela Dostalova, Alejandro Fainboim, Andreas Fellgiebel, Cassiano Forcelini, Kristina An Haack, Robert J Hopkin, Michael Mauer, Behzad Najafian, C Ronald Scott, Suma P Shankar, Beth L Thurberg, Camilla Tøndel, Anna Tylki-Szymańska, Uma Ramaswami
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0124987 (2015)
Trial designThis analysis characterizes the degree of early organ involvement in a cohort of oligo-symptomatic untreated young patients with Fabry disease enrolled in an ongoing randomized, open-label, parallel-group, phase 3B clinical trial.MethodsM
Externí odkaz:
https://doaj.org/article/d2e2eaf3e691443aac855665f5d88ee5
Autor:
Rhona M, Jack, C Ronald, Scott
Publikováno v:
JIMD Reports
The drug nitisinone (NTBC; Orfadin, Vienna, Austria) has been used for the treatment of hereditary tyrosinemia type‐1 since 1991. Nitisinone effectively blocks the metabolism of tyrosine to prevent the formation of the toxic compound succinylaceton
Autor:
Xinying, Hong, Jessica, Daiker, Martin, Sadilek, Nicole, Ruiz-Schultz, Arun Babu, Kumar, Stevie, Norcross, Warunee, Dansithong, Teryn, Suhr, Maria L, Escolar, C, Ronald Scott, Andreas, Rohrwasser, Michael H, Gelb
Publikováno v:
Genetics in medicine : official journal of the American College of Medical Genetics. 23(3)
Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder caused by the deficiency of arylsulfatase A (ARSA), which results in the accumulation of sulfatides. Newborn screening for MLD may be considered in the future as innovative treatments
Autor:
Can Ficicioglu, Katie Coakley, Clara D.M. van Karnebeek, Markus Grompe, Melissa P. Wasserstein, Jeffrey M. Chinsky, Grant A. Mitchell, Muge Gucsavas-Calikoglu, Susan E. Waisbren, C. Ronald Scott, Rani H. Singh
Publikováno v:
Genetics in medicine, 19(12):1380. Lippincott Williams and Wilkins
Genetics in Medicine
Genetics in Medicine
Tyrosinemia type I (hepatorenal tyrosinemia, HT-1) is an autosomal recessive condition resulting in hepatic failure with comorbidities involving the renal and neurologic systems and long term risks for hepatocellular carcinoma. An effective medical t
Autor:
František Tureček, Farideh Ghomashchi, C. Ronald Scott, Joseph J. Orsini, Joanne Kurtzberg, Hsuan-Chieh Liao, Zdenek Spacil, Michael H. Gelb, Maria L. Escolar
Publikováno v:
Clinical Chemistry. 63:1363-1369
BACKGROUND Deficiency of the lysosomal enzyme galactosylcerebrosidase (GALC) causes Krabbe disease. Newborn screening for Krabbe disease is ongoing, but improved methods for follow-up analysis of screen-positive babies are needed to better advise fam
Autor:
Joel Charrow, Manisha Balwani, Hans C. Andersson, Thomas A. Burrow, Barry E. Rosenbloom, Neal J. Weinreb, Edwin H. Kolodny, Aneal Khan, Priya S. Kishnani, Julie L. Batista, C. Ronald Scott, Pramod K. Mistry, Paige Kaplan
Publikováno v:
American Journal of Hematology
This study tests the hypothesis that the prevalence of severe clinical manifestations in Gaucher disease type 1 (GD1) patients at the time of treatment initiation has changed since alglucerase/imiglucerase enzyme replacement therapy (ERT) was approve
Publikováno v:
Pediatrics. 140:S4-S13
Started in 1963 by Robert Guthrie, newborn screening (NBS) is considered to be one of the great public health achievements. Its original goal was to screen newborns for conditions that could benefit from presymptomatic treatment, thereby reducing ass